Clinical Trials for Mesothelioma Patients: Novartis LBH589 Exclusion Criteria

Read about the exclusion criteria for a current clinical trial being conducted to study the effects of Novartis LBH589 for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. For additional information, contact Novartis at 1-800-340-6843.

Exclusion criteria

1. Known brain metastases

2. Prior treatment with an HDAC inhibitor

3. Presence of clinically detectable third-space fluid collections (e.g., ascites or pleural effusions) that can be controlled by drainage or other procedures prior to study entry

4. Concomitant use of any anti-cancer therapy, including radiation therapy

5. Significant cardiac disease

6. Concomitant use of drugs with a risk of causing torsades de pointes

7. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral LBH589

8. Previous use of monoamine oxidase inhibitors (e.g. clorgyline, iproniazid, isocarboxazid, moclobemide, sibutramine, phenelzine, tranylcypromine) within 14 days prior to the first dose of dextromethorphan

Other protocol-defined inclusion/exclusion criteria may apply

If you or a loved one has been diagnosed with an asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.